Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Medexus Pharmaceuticals Inc (TSE:MDP)
TSX:MDP
MDP Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$1.47 - C$5.56
Previous CloseN/A
Volume43.25K
Average Volume (3M)189.45K
Market Cap
C$99.35M
Enterprise ValueC$130.64M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)15.5
Beta0.99
Next Earnings
Jul 01, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.20
Shares Outstanding32,152,493
10 Day Avg. Volume145,754
30 Day Avg. Volume189,446
Standard Deviation0.24
R-Squared0.12
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.67
Price to Cash Flow (P/CF)2.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$5.62Price Target Upside81.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Medexus Pharmaceuticals Inc News
PremiumCompany Announcements
Medexus Pharmaceuticals: Robust Earnings Amidst Challenges
PremiumCompany Announcements
Medexus Secures Ontario Public Reimbursement for Trecondyv
PremiumCompany Announcements
Medexus Pharmaceuticals Announces $30 Million Public Offering---
Bulls Say, Bears Say
Bulls Say
Drug ApprovalU.S. FDA approves Treosulfan, marking a significant benefit to patients.
Financial PerformanceMedexus's FQ3 results were ahead of initial estimates, showing strong performance.
Bears Say
Generic RiskThere is generic risk in the base business with Rupall losing exclusivity.
Pricing AssumptionsInitial pricing assumptions for GRAFAPEX appear optimistic.
Regulatory SetbackMedexus faces a negative Health Canada setback for Terbinafine.
---
Options Prices
Currently, No data available
---
Ownership Overview
7.38% Insiders
0.40% Mutual Funds
0.03% Other Institutional Investors
92.18% Public Companies and
Individual Investors
MDP FAQ
What was Medexus Pharmaceuticals Inc’s price range in the past 12 months?
Medexus Pharmaceuticals Inc lowest stock price was C$1.47 and its highest was C$5.56 in the past 12 months.
What is Medexus Pharmaceuticals Inc’s market cap?
Medexus Pharmaceuticals Inc’s market cap is C$99.35M.
When is Medexus Pharmaceuticals Inc’s upcoming earnings report date?
Medexus Pharmaceuticals Inc’s upcoming earnings report date is Jul 01, 2025 which is in 134 days.
How were Medexus Pharmaceuticals Inc’s earnings last quarter?
Medexus Pharmaceuticals Inc released its earnings results on Feb 05, 2025. The company reported C$0.043 earnings per share for the quarter, missing the consensus estimate of C$0.051 by -C$0.009.
Is Medexus Pharmaceuticals Inc overvalued?
According to Wall Street analysts Medexus Pharmaceuticals Inc’s price is currently Undervalued.
Does Medexus Pharmaceuticals Inc pay dividends?
Medexus Pharmaceuticals Inc does not currently pay dividends.
What is Medexus Pharmaceuticals Inc’s EPS estimate?
Medexus Pharmaceuticals Inc’s EPS estimate is -0.1.
How many shares outstanding does Medexus Pharmaceuticals Inc have?
Medexus Pharmaceuticals Inc has 32,152,493 shares outstanding.
What happened to Medexus Pharmaceuticals Inc’s price movement after its last earnings report?
Medexus Pharmaceuticals Inc reported an EPS of C$0.043 in its last earnings report, missing expectations of C$0.051. Following the earnings report the stock price went down -19.525%.
Which hedge fund is a major shareholder of Medexus Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in TSE:MDP
---
Medexus Pharmaceuticals Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$5.62 (81.88% Upside)
C$5.62 (81.88% Upside)
Insider Transactions
Bought Shares
Worth C$50.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.59%
12-Months-Change
Fundamentals
Return on Equity
11.27%
Trailing 12-Months
Asset Growth
-0.72%
Trailing 12-Months
Company Description
Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.
---
MDP Stock 12 Month Forecast
Average Price Target
C$5.62
▲(81.88% Upside)
Technical Analysis
Theratechnologies
―
Knight Therapeutics
―
HLS Therapeutics Inc
―
Premier Health of America Inc
―
Best Analysts Covering MDP
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+51.11%
reiterated a buy rating 10 days ago
Copying David Martin PhD's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +51.11% per trade.
---